Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies

Fig. 5

Anti-CCL20 antibody significantly reduces RGC loss, microgliosis, Müller cell activation and CCL20 expression in the retina. a Representative immunofluorescence images showing RGC (H&E), Iba1 (red), GFAP (green), or CCL20 (bright field) immunoreactivity in the retina with or without anti-CCL20 antibody or isotype treatment 7 days after rTBI. Scale bar 100 μm. Inset high-magnification images showing CCL20 expression in the retinal ganglionic cells, scale bar 20 μm. Blue fluorescence shows DAPI. be Histograms showing average count of RGC (b), Iba1-positive cells (c), average fluorescence intensity of GFAP immunoreactivity (d), or CCL20 immunoreactivity (e) as quantitated by ImageJ. f CCL20 protein expression in the retina as estimated by Quantikine ELISA. *p < 0.01, **p < 0.001, ***p < 0.0001

Back to article page